Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | AKT2 | P31751 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.50 |
| ▸ | CSF1R | P07333 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5820038 | 0.81 | MAPK1 (1.00) | MAPK1NPSR1AKT2KMT2AL3MBTL1 | |
| SCHEMBL19926065 | 0.81 | GSK3A (0.57) | MAPK1NPSR1AKT2KMT2AL3MBTL1 | |
| SCHEMBL1278851 | 0.79 | MAPK1 (0.48) | MAPK1NPSR1AKT2KMT2AL3MBTL1 | |
| SCHEMBL1057636 | 0.79 | AKT2 (0.66) | MAPK1NPSR1AKT2KMT2AL3MBTL1 | |
| SCHEMBL544723 | 0.79 | AKT2 (1.00) | MAPK1NPSR1AKT2KMT2AL3MBTL1 | |
| SCHEMBL12464662 | 0.79 | RPS6KA3 (0.49) | MAPK1NPSR1AKT2KMT2AL3MBTL1 | |
| SCHEMBL13516075 | 0.79 | IKBKB (0.68) | MAPK1NPSR1AKT2KMT2ARPS6KA3 | |
| SCHEMBL20931277 | 0.75 | MAPK1 (0.44) | MAPK1NPSR1AKT2KMT2AL3MBTL1 | |
| SCHEMBL20836964 | 0.75 | GSK3B (0.47) | MAPK1NPSR1AKT2KMT2AL3MBTL1 | |
| SCHEMBL18704445 | 0.75 | MAPK1 (0.44) | MAPK1NPSR1AKT2KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| WO-2019055750-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-1778718-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8603917-B2 | Method of processing a wafer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-12-10 | — | — | US | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-8110568-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110046066-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20100256115-A1 | INHIBITORS OF IAP | COHEN FREDERICK | 2010-10-07 | — | — | US | disclosed |
| US-20100256115-A1 | INHIBITORS OF IAP | COHEN FREDERICK | 2010-10-07 | — | — | US | disclosed |
| WO-2009089502-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2008134679-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | MAPK1 574/4885NPSR1 971/4885AKT2 405/4885 |
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | MAPK1 2166/4885NPSR1 1546/4885AKT2 3244/4885 |
| US-20070299052-A1 | Inhibitors of IAP | XIAP, BIRC5, BIRC3 | MAPK1 3051/4885NPSR1 3542/4885AKT2 2270/4885 |
| US-20110046066-A1 | INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | MAPK1 2743/4885NPSR1 4040/4885AKT2 2155/4885 |
| US-20100256115-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC3 | MAPK1 3051/4885NPSR1 3542/4885AKT2 2270/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | MAPK1 2166/4885NPSR1 1546/4885AKT2 3244/4885 |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | PASK, PDXK, PANK2 | MAPK1 574/4885NPSR1 971/4885AKT2 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.